MX383499B - Agentes terapeuticos para enfermedades neurodegenerativas - Google Patents
Agentes terapeuticos para enfermedades neurodegenerativasInfo
- Publication number
- MX383499B MX383499B MX2019001575A MX2019001575A MX383499B MX 383499 B MX383499 B MX 383499B MX 2019001575 A MX2019001575 A MX 2019001575A MX 2019001575 A MX2019001575 A MX 2019001575A MX 383499 B MX383499 B MX 383499B
- Authority
- MX
- Mexico
- Prior art keywords
- neurodegenerative diseases
- therapeutic agents
- leucine
- present disclosure
- pharmaceutically acceptable
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 abstract 1
- 229960000669 acetylleucine Drugs 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Transplantation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1613829.9A GB201613829D0 (en) | 2016-08-11 | 2016-08-11 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| GBGB1702551.1A GB201702551D0 (en) | 2017-02-16 | 2017-02-16 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| GBGB1705766.2A GB201705766D0 (en) | 2017-04-10 | 2017-04-10 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| GBGB1706867.7A GB201706867D0 (en) | 2017-04-28 | 2017-04-28 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| PCT/IB2017/054929 WO2018029658A1 (en) | 2016-08-11 | 2017-08-11 | Therapeutic agents for neurodegenerative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019001575A MX2019001575A (es) | 2019-08-01 |
| MX383499B true MX383499B (es) | 2025-03-14 |
Family
ID=59859424
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019001575A MX383499B (es) | 2016-08-11 | 2017-08-11 | Agentes terapeuticos para enfermedades neurodegenerativas |
| MX2021006901A MX2021006901A (es) | 2016-08-11 | 2019-02-07 | Agentes terapeuticos para enfermedades neurodegenerativas. |
| MX2024004439A MX2024004439A (es) | 2016-08-11 | 2024-04-11 | Agentes terapeuticos para enfermedades neurodegenerativas |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021006901A MX2021006901A (es) | 2016-08-11 | 2019-02-07 | Agentes terapeuticos para enfermedades neurodegenerativas. |
| MX2024004439A MX2024004439A (es) | 2016-08-11 | 2024-04-11 | Agentes terapeuticos para enfermedades neurodegenerativas |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US12144792B2 (enExample) |
| EP (3) | EP3583940A1 (enExample) |
| JP (3) | JP6957602B2 (enExample) |
| KR (4) | KR20220093385A (enExample) |
| CN (4) | CN116492328A (enExample) |
| AU (3) | AU2017308865B2 (enExample) |
| BR (1) | BR112019002730A2 (enExample) |
| CA (1) | CA3033564A1 (enExample) |
| CY (1) | CY1121930T1 (enExample) |
| DK (1) | DK3416631T3 (enExample) |
| ES (1) | ES2733677T3 (enExample) |
| HR (1) | HRP20191055T1 (enExample) |
| HU (1) | HUE045043T2 (enExample) |
| IL (3) | IL310799A (enExample) |
| LT (1) | LT3416631T (enExample) |
| MA (2) | MA47521A (enExample) |
| MD (1) | MD3416631T2 (enExample) |
| ME (1) | ME03454B (enExample) |
| MX (3) | MX383499B (enExample) |
| PL (1) | PL3416631T3 (enExample) |
| PT (1) | PT3416631T (enExample) |
| RS (1) | RS59048B1 (enExample) |
| RU (1) | RU2756519C2 (enExample) |
| SG (1) | SG11201901063SA (enExample) |
| SI (1) | SI3416631T1 (enExample) |
| SM (1) | SMT201900370T1 (enExample) |
| TN (1) | TN2019000033A1 (enExample) |
| WO (1) | WO2018029658A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10219815B2 (en) | 2005-09-22 | 2019-03-05 | The Regents Of The University Of Michigan | Histotripsy for thrombolysis |
| JP6979882B2 (ja) | 2015-06-24 | 2021-12-15 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | 脳組織の治療のための組織破砕療法システムおよび方法 |
| HUE052837T2 (hu) | 2016-08-11 | 2021-05-28 | Intrabio Ltd | Lizoszóma-tárolási betegségre irányuló gyógyászati készítmények és alkalmazásaik |
| BR112019002730A2 (pt) | 2016-08-11 | 2019-05-14 | Intrabio Ltd | acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa |
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| SMT202500483T1 (it) * | 2017-10-18 | 2026-01-12 | Intrabio Ltd | Agenti terapeutici da utilizzare nel trattamento della sindrome delle gambe senza riposo |
| SI3752141T1 (sl) * | 2018-02-15 | 2024-09-30 | Intrabio Ltd. | Acetil-levcin za uporabo pri zdravljenju sindroma nemirnih nog |
| CN113286552B (zh) | 2018-11-28 | 2025-05-02 | 希斯托索尼克斯公司 | 组织摧毁术系统及方法 |
| KR20250022899A (ko) * | 2018-12-06 | 2025-02-17 | 인트라바이오 리미티드 | 아세틸-류신의 중수소화된 유사체 |
| SG11202109512SA (en) * | 2019-03-02 | 2021-09-29 | Intrabio Ltd | Leucine, acetyl leucine, and related analogs for treating disease |
| WO2021055443A1 (en) * | 2019-09-17 | 2021-03-25 | Hoffmann-La Roche Inc. | Improvements in personalized healthcare for patients with movement disorders |
| WO2021144720A1 (en) * | 2020-01-13 | 2021-07-22 | Intrabio Ltd | Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers |
| CA3179105A1 (en) * | 2020-05-22 | 2021-11-25 | Michael Strupp | The combination of acetyl leucine and 4-aminopyridine or acetazolamide for treating ataxia |
| WO2022264037A1 (en) * | 2021-06-14 | 2022-12-22 | Intrabio Ltd. | Branched-chain amino acid derivatives to treat disease |
| US20240149078A1 (en) | 2022-10-28 | 2024-05-09 | Histosonics, Inc. | Histotripsy systems and methods |
| KR20260003742A (ko) | 2023-04-20 | 2026-01-07 | 히스토소닉스, 인크. | 치료 계획 및 요법을 위한 사용자 인터페이스들 및 작업 흐름들을 포함하는 히스토트립시 시스템들 및 연관된 방법들 |
| WO2025151578A1 (en) * | 2024-01-12 | 2025-07-17 | Intrabio Inc. | N-acetyl-leucine for use in the treatment of prodromal alpha-synucleinopathies |
| WO2025163129A1 (en) * | 2024-02-01 | 2025-08-07 | Intrabio Ltd. | Acetyl-leucine for treating parkinson´s disease |
| US12403111B2 (en) | 2024-02-02 | 2025-09-02 | SynGAP Research Fund | Compositions and methods for treating neurodevelopmental disorders |
| WO2025175092A1 (en) * | 2024-02-14 | 2025-08-21 | Intrabio Inc. | Acetyl leucine for treating syngap1-related disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| US20050222209A1 (en) * | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| FR2905600B1 (fr) | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| WO2008101693A2 (en) | 2007-02-22 | 2008-08-28 | Beiersdorf Ag | Cosmetic and pharmaceutical applications of n-acylated amino acids and structurally related compounds |
| TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| TN2010000566A1 (en) * | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
| EP3062810A4 (en) * | 2013-10-28 | 2017-05-03 | Naurex Inc. | Nmda receptor modulators and prodrugs, salts, and uses thereof |
| HUE069219T2 (hu) | 2016-04-19 | 2025-02-28 | Intrabio Ltd | Acetil-leucin vagy gyógyszerészetileg elfogadható sója javított mozgásképességért |
| BR112019002730A2 (pt) | 2016-08-11 | 2019-05-14 | Intrabio Ltd | acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa |
-
2017
- 2017-08-11 BR BR112019002730-0A patent/BR112019002730A2/pt not_active Application Discontinuation
- 2017-08-11 PL PL17767934T patent/PL3416631T3/pl unknown
- 2017-08-11 CN CN202310629563.6A patent/CN116492328A/zh active Pending
- 2017-08-11 WO PCT/IB2017/054929 patent/WO2018029658A1/en not_active Ceased
- 2017-08-11 LT LTEP17767934.7T patent/LT3416631T/lt unknown
- 2017-08-11 CA CA3033564A patent/CA3033564A1/en active Pending
- 2017-08-11 SG SG11201901063SA patent/SG11201901063SA/en unknown
- 2017-08-11 EP EP19174007.5A patent/EP3583940A1/en active Pending
- 2017-08-11 KR KR1020227021012A patent/KR20220093385A/ko not_active Ceased
- 2017-08-11 US US16/324,353 patent/US12144792B2/en active Active
- 2017-08-11 CN CN202310627214.0A patent/CN116459244A/zh active Pending
- 2017-08-11 TN TNP/2019/000033A patent/TN2019000033A1/fr unknown
- 2017-08-11 ME MEP-2019-169A patent/ME03454B/me unknown
- 2017-08-11 KR KR1020197007032A patent/KR102413756B1/ko active Active
- 2017-08-11 KR KR1020247014635A patent/KR102785448B1/ko active Active
- 2017-08-11 HR HRP20191055TT patent/HRP20191055T1/hr unknown
- 2017-08-11 SM SM20190370T patent/SMT201900370T1/it unknown
- 2017-08-11 KR KR1020257008819A patent/KR20250042197A/ko active Pending
- 2017-08-11 EP EP17767934.7A patent/EP3416631B1/en active Active
- 2017-08-11 HU HUE17767934A patent/HUE045043T2/hu unknown
- 2017-08-11 AU AU2017308865A patent/AU2017308865B2/en active Active
- 2017-08-11 RU RU2019106506A patent/RU2756519C2/ru active
- 2017-08-11 RS RS20190801A patent/RS59048B1/sr unknown
- 2017-08-11 MA MA047521A patent/MA47521A/fr unknown
- 2017-08-11 DK DK17767934.7T patent/DK3416631T3/da active
- 2017-08-11 IL IL310799A patent/IL310799A/en unknown
- 2017-08-11 CN CN202511449973.8A patent/CN121081445A/zh active Pending
- 2017-08-11 SI SI201730071T patent/SI3416631T1/sl unknown
- 2017-08-11 IL IL310801A patent/IL310801A/en unknown
- 2017-08-11 EP EP24191483.7A patent/EP4467195A3/en active Pending
- 2017-08-11 JP JP2019507819A patent/JP6957602B2/ja active Active
- 2017-08-11 CN CN201780059708.6A patent/CN109789114A/zh active Pending
- 2017-08-11 IL IL264641A patent/IL264641B2/en unknown
- 2017-08-11 PT PT17767934T patent/PT3416631T/pt unknown
- 2017-08-11 ES ES17767934T patent/ES2733677T3/es active Active
- 2017-08-11 MD MDE20190027T patent/MD3416631T2/ro unknown
- 2017-08-11 MA MA43828A patent/MA43828B1/fr unknown
- 2017-08-11 MX MX2019001575A patent/MX383499B/es unknown
-
2019
- 2019-02-07 MX MX2021006901A patent/MX2021006901A/es unknown
- 2019-07-16 CY CY20191100759T patent/CY1121930T1/el unknown
-
2021
- 2021-10-06 JP JP2021164793A patent/JP7833272B2/ja active Active
-
2023
- 2023-03-15 US US18/183,972 patent/US20230210799A1/en active Pending
- 2023-04-05 AU AU2023202121A patent/AU2023202121B2/en active Active
- 2023-09-08 JP JP2023146465A patent/JP2023175762A/ja active Pending
-
2024
- 2024-01-12 US US18/411,512 patent/US20240189267A1/en active Pending
- 2024-04-11 MX MX2024004439A patent/MX2024004439A/es unknown
-
2025
- 2025-03-21 AU AU2025202077A patent/AU2025202077A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024004439A (es) | Agentes terapeuticos para enfermedades neurodegenerativas | |
| GB201820166D0 (en) | Therapeutic agents | |
| PT3600309T (pt) | Combinações terapêuticas para o tratamento de doenças hepáticas | |
| GB201820165D0 (en) | Therapeutic agents | |
| MX379043B (es) | Uso de sobetirome en el tratamiento de enfermedades de mielinización. | |
| PH12017500493A1 (en) | Combination therapy | |
| MX386547B (es) | Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer. | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
| IL281869B1 (en) | Medical cause for degenerative nerve disease | |
| EA201892265A1 (ru) | Способы лечения офтальмологических заболеваний | |
| GB201805816D0 (en) | Therapeutic agents | |
| IL264603A (en) | Reelin compositions for treatment of neurological disorders | |
| IL273929A (en) | Therapeutic agents for neurodegenerative diseases | |
| BR112019004791A2 (pt) | tratamento de esclerose múltipla com chs-131 | |
| CY1119522T1 (el) | (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| PH12017501955A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease | |
| MX384394B (es) | Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas. | |
| AR109209A1 (es) | Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas | |
| GB201820168D0 (en) | Therapeutic agents | |
| GB201820162D0 (en) | Therapeutic agents | |
| GB201820172D0 (en) | Therapeutic agents | |
| GB201820170D0 (en) | Therapeutic agents | |
| GB201820160D0 (en) | Therapeutic agents | |
| GB201820164D0 (en) | Therapeutic agents | |
| GB201811753D0 (en) | Therapeutic agents |